? February brought plenty of #LBx news, including numerous partnerships and collaborations, fundraising, and study data.?? ? Clinical and Regulatory? Natera announced that its Signatera test has received coverage from the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Services Program (MolDX) for NSCLC patients. ClearNote Health announced that their Avantect Pancreatic Cancer Test has been approved by the New York State Department of Health, making it available to clinicians in New York as a tool for pancreatic cancer early detection (EDx). Labcorp also launched its new Plasma Complete ctDNA CGP solution last month, designed to guide treatment decisions for advanced tumors.? ? Company Announcements & Product Launches? Foresight Diagnostics announced the expansion of their strategic collaboration with Allogene Therapeutics. Lynx Dx has launched ordering of its MyProstateScore 2.0 test’s at-home collection format. The test is ordered by physicians and is eligible for Medicare reimbursement. Meanwhile, Flatiron Health and Exact Sciences have announced a new collaboration aimed at generating clinical evidence for Exact’s MRD test, called Oncodetect, across a range of solid tumors. The first patient has already been enrolled.? ? Clinical Trials & Study Results? Researchers from the University of Washington and Fred Hutchinson Cancer Center have demonstrated the value of a prenatal cfDNA WGS assay for predicting preeclampsia. The test achieved 81% and 79% sensitivity in validation and external cohort analysis, respectively. A new pancreatic ductal adenocarcinoma (PDAC) assay was developed at Oregon Health & Science University. ? M&A | VC | Private Equity | Legal? PacBridge Capital Partners has backed AI health tech startup Avitia with $5M in seed funding. Avitia’s technology aims to enable cancer centers to perform NGS tests in-house, thereby improving affordability and accessibility. Syantra Inc. has received funding from Alberta Innovates to expand clinical studies of its Onco-ID: Breast screening test. The funding complements funding from the US DoD and will support a pilot study at the Mays Cancer Center at UT Health San Antonio. Oncocyte Corporation has raised $29.1M through concurrent offering to existing investors and private placements to fund its FDA IVD transplant assay program.? ? ? Read the newsletter for more:??https://lnkd.in/gGueNDjq ? Sign up to receive our Liquid Biopsy Newsletter in your email:?https://lnkd.in/gKQn7_zp ? The headlines have been handcrafted by Amal Thommil, Graham F., Nila Venkat, and Antony Awad?? ? #cancerdetection #earlydetection #precisionmedicine #productlaunches #cancermonitoring #liquidbiopsytesting?
Thank you for mentioning our news!